Veracyte, Inc. (VCYT) Financial Statements
Veracyte, Inc. (VCYT) reported trailing twelve-month revenue of $561.9M (up 17.3% year on year) and net income of $114.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $166.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VCYTVeracyte, Inc.Follow VCYT — free
—
Price chart with a free account
- Market cap
- 3.9B
- P/E TTM
- 34.2
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.02 | 0.04 | 0.05 | 0.07 | 0.07 | 0.09 | 0.12 | 0.12 | 0.22 | 0.30 | 0.36 | 0.45 | 0.52 | 0.56 | |
| Gross profit | 0.01 | 0.02 | 0.03 | 0.04 | 0.04 | 0.06 | 0.08 | — | 0.15 | 0.19 | 0.23 | 0.30 | 0.36 | 0.40 | |
| Research & development | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 | 0.06 | 0.07 | 0.07 | 0.09 | |
| Operating income | -0.02 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.02 | -0.04 | -0.08 | -0.04 | -0.09 | 0.02 | 0.06 | 0.11 | |
| Pre-tax income | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.01 | -0.03 | -0.08 | -0.04 | -0.08 | 0.03 | 0.07 | 0.12 | |
| Income tax | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | |
| Net income | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 | -0.01 | -0.03 | -0.08 | -0.04 | -0.07 | 0.02 | 0.07 | 0.11 | |
| Diluted EPS ($) | -6.15 | -1.36 | -1.30 | -1.09 | -0.91 | -0.62 | -0.27 | -0.66 | -1.11 | -0.51 | -1.02 | 0.31 | 0.82 | 1.40 | |
| Diluted shares (bn) | — | — | — | — | — | — | — | — | 0.068 | 0.072 | 0.073 | 0.078 | 0.081 | — |
USD billions · SEC XBRL
Veracyte, Inc. — questions
- What is Veracyte, Inc.'s revenue?
- $561.9M over the twelve months to 2026-06-30, up 17.3% year on year, from its 10-Q and 10-K filings.
- What is Veracyte, Inc.'s net income?
- $114.5M over the twelve months to 2026-06-30.
- What is Veracyte, Inc.'s free cash flow?
- $166.0M over the twelve months to 2026-06-30.
- What are Veracyte, Inc.'s diluted earnings per share?
- $1.40 over the twelve months to 2026-06-30.
Every figure on this page comes from Veracyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.